Prof. Peter J. Wild


Principal Investigator
peter.wild {at}
List of Publication
Curriculum Vitae
Scopus Author Identifier
Read More


Peter Wild is Full Professor for Systems Pathology and Senior Consultant Pathologist at the University of Zurich (UZH) and University Hospital of Zurich (USZ). Since 2017 he is also Chief Scientific Officer (CSO) of the Foundation Medicine Lab at the University Hospital Zurich.


Among the main achievements of Peter Wild are that he has established and validated next-generation-sequencing technologies including whole exome sequencing for diagnostic molecular pathology, established the Molecular Tumorboard Zurich (MTBZ), characterized the first mouse model of type II endometrial carcinomas, generated a seven-marker signature for clinical outcome in malignant melanoma, screened a library of small interfering RNAs for glycoproteome genes whose inhibition causes synthetic lethality with the PTEN gene in prostate cancer cells in vitro, and generated comprehensive cancer tissue microarrays of large patient cohorts (prostate, breast, bladder, skin cancer).


He is a graduate of the University of Regensburg Medical School in Germany, and has completed a postdoctoral training in Medical Biometrics at the University of Heidelberg, Germany. In 2002, he has finished his doctoral thesis in pathology (summa cum laude) in the laboratory of Ferdinand Hofstädter and Arndt Hartmann on predictive biomarkers of patients with advanced breast cancer at the University Hospital Regensburg. For his residency training in pathology, he went to the Institutes of Pathology at the University Hospitals in Regensburg, Hamburg-Eppendorf, and Zurich. In 2008 and 2010, he received the German and the Swiss Board Certification in Pathology, respectively. For a two year postdoctoral research training, he joined the laboratory of Wilhelm Krek at ETH Zurich to investigate the role of the PI3K-AKT-mTOR signalling pathway in cancer and its use for diagnostic serum signatures and functional studies. In April 2010 he also received his Venia Legendi in Pathology from the University of Zurich for his work on molecular biomarkers of bladder cancer. In September 2012, Peter Wild was appointed Assistant Professor (tenure track) for Systems Pathology, leading the High-Throughput Genomics Laboratory at the USZ.


Peter Wild has received several awards, including the Rudolf-Virchow-Preis (2013) of the German Society of Pathology, the Young Investigator Award for Cancer Research of the Charles Rodolphe Brupbacher Foundation (2007), and the Research Award of the Novartis Foundation for Therapeutical Research (2004).


Dr. Dorothea Rutishauser


Postdoctoral Research Fellow​
dorothea.rutishauser {at}
Read More


Current Research Projects

Selected Publication
Curriculum Vitae 


2016 Postdoctoral Fellow in the Wild Lab, Proteomics Coordination, Institute of Surgical Pathology, University Hospital Zurich, Switzerland
2010-2016 Project Leader PK/KI, Proteomics Karolinska, Department of Medical Biochemistry and Biophysics; Core Facility Manager of Advanced Proteomics at SciLifeLab Stockholm, Sweden
2007-2010 Senior Scientist, Functional Genomics Center Zurich, ETH Zurich, Switzerland
2007 PhD, Institute of Neuropathology, University Hospital of Zurich, Switzerland


Dr. Laura De Vargas Roditi


Laura Postdoctoral Research Fellow
laura.deVargas {at}
Read More


Computational analysis of single-cell resolved prostate cancer data

Prostate cancer is the most commonly diagnosed cancer amongst males. Castration-resistant prostate cancer is the second most common cause of cancer-related deaths in men. Typically, prostate cells, including cancerous ones, depend on androgens, such as testosterone, which are normally produced in the testicles; therefore the first line of treatment for prostate cancer patients consists of androgen ablation through surgical or chemical castration. This treatment leads to temporary disease regression but often fails after development of castration-resistant prostate cancer.


Prostate cancer is characterized by multiple genomic alterations leading to the complex nature and heterogeneity of the disease. Intra-tumor heterogeneity can impair precise molecular analysis of tumors and interferes with biomarker qualification, treatment personalization as well as drives therapy resistance, highlighting the importance of characterizing tumor heterogeneity.
Current Research Projects 

Single cell analysis of prostate cancer tissue using mass cytometry.


Research Interests

Using mathematical and computational modeling to analyze high-dimensional single-cell data with the goal of characterizing cancer heterogeneity, describing the cancers’ evolutionary trajectory, and to help develop new therapeutic approaches for the treatment of cancer.



Kathrin Oehl


Kathrin PhD Student
kathrin.oehl {at}


Elisa Bellini


Elisa PhD Student
elisa.bellini {at}
Read More


Identification of the molecular drivers of Endometrial Cancer progression

Endometrial carcinoma is the most common malignancy of the female genital tract. Although PI3K-mTOR pathway activation and TP53 inactivation play different roles in the initiation of different endometrial cancer subtypes, co-occurring alterations in both signaling pathways represent a frequent unifying pathogenic feature of late stage tumors of all subtypes.
Our aim is to identify and functionally assess the role of the proteins crucial for the survival of endometrial cancer cells with the aforementioned molecular signature. For this purpose, we designed a PI3K pathway-dependent synthetic lethality screen using RNAi technology and used TALEN (TAL-effector nuclease) genome editing tool to knock-out PTEN (an important inhibitor of the PI3K pathway) in TP53-/- endometrial carcinoma cell lines.
To confirm the aberrations critical for disease progression and assign them to each step of endometrial cancer development, we will further investigate the obtained results using the tissue microarrays (TMAs), containing a very large cohort of human endometrial cancer tissues, available at the Tissue-Biobank of our Institute.
Ultimately, this approach aims at using the knowledge gained from the cell culture model to decipher mechanisms commonly involved in the progression of the endometrial cancer of patients. The final goal is to characterize new prognostic and potentially predictive markers for improving personalised molecular diagnosis and treatment.

Figure. Synthetic lethality is a type of genetic interaction where the co-occurrence of two genetic events results in organismal or cellular death.


Malamati (Elina) Koletou


Elisa PhD Student
malamati.koletou {at}
Read More

Figure 1. Data from TCGA (The Cancer Genome Atlas).
We aim to search for prostate cancer specific genomic alterations and infer patterns across different types of omics datasets in order to improve the stratification of prostate cancer in two classes, significant and insignificant disease.

Figure 2. Pattern detection via dictionary learning.
We are developing a novel computational framework that offers a novel perspective into analysing genomic data from relatively very small number of samples and that can integrate multiple omics datasets.



Dr. Markus Rechsteiner

Dr. Qing Zhong (CMRI, The University of Sydney)

Dr. Christine Fritz

Dr. Nadejda Valtcheva

Dr. Ulrich Wagner

Dr. Nadezda Velizheva

Dr. Sandra Freiberger

Dr. Ana Filipa Goncalves

Dr. Ailsa Christiansen

Dr. med. Jan Hendrik Rüschoff

Dr. med. Kristian Ikenberg

Dr. med. Niels Rupp

Dr. med. Kim Fricker

Dr. med. Christian D. Fankhauser

Dr. med. Karim Saba

Annette Bohnert von Rotz

Jelena Ljubicic